Modality
Radioligand
MOA
CGRPant
Target
MET
Pathway
STING
MCLBreast Ca
Development Pipeline
Preclinical
~Feb 2021
→ ~May 2022
Phase 1
~Aug 2022
→ ~Nov 2023
Phase 2
Feb 2024
→ Nov 2031
Phase 2Current
NCT08660786
2,751 pts·Breast Ca
2024-02→2031-11·Not yet recruiting
NCT05963359
2,519 pts·Breast Ca
2025-04→2026-01·Completed
5,270 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-01-033mo agoPh2 Data· Breast Ca
2031-11-025.6y awayPh2 Data· Breast Ca
Trial Timeline
2024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P2
Not yet…
P2
Complet…
Catalysts
Ph2 Data
2026-01-03 · 3mo ago
Breast Ca
Ph2 Data
2031-11-02 · 5.6y away
Breast Ca
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08660786 | Phase 2 | Breast Ca | Not yet recr... | 2751 | DOR |
| NCT05963359 | Phase 2 | Breast Ca | Completed | 2519 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET | |
| INC-2432 | Incyte | Phase 2 | CD47 | |
| Sematapinarof | Legend Biotech | NDA/BLA | VEGF | |
| Rilufotisoran | Samsung Biologics | NDA/BLA | FXIa |